Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

AGM Resolutions Passed

23 Jul 2008 12:36

RNS Number : 7131Z
Celsis International PLC
23 July 2008
 



Stock Exchange announcement

FOR release: Wednesday 23 July 2008

CELSIS INTERNATIONAL PLC

("Celsis", "the Company" or "the Group")

Results of AGM

23 July 2008: At the Annual General Meeting of Celsis, held today, all resolutions were duly passed.

Enquiries:

Celsis International plc

Tel: +44 (0) 1223 598 428

Jay LeCoque, Chief Executive Officer

Jenny Woolway, Corporate Communications

Financial Dynamics

Tel: +44 (020 7831 3113

David Yates

Jonathan Birt

Notes to editors

Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).

Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. 

Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. 

Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. 

Further information can be found on its website at www.celsis.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFKNKNDBKDDOB
Date   Source Headline
4th Aug 20058:00 amRNSDirector/PDMR Shareholding
26th Jul 20055:07 pmRNSResult of AGM
26th Jul 20057:00 amRNSAGM Statement
18th Jul 20054:35 pmRNSDividend Declaration
11th Jul 20054:58 pmRNSHolding(s) in Company
30th Jun 200511:42 amRNSAnnual Report and Accounts
28th Jun 20057:01 amRNSRe: Share Capital
10th Jun 20053:38 pmRNSTreasury Stock
6th Jun 20054:59 pmRNSDirector Shareholding
2nd Jun 200511:03 amRNSHolding(s) in Company
31st May 20059:07 amRNSDirector Shareholding
24th May 20057:01 amRNSFinal Results
16th May 20054:08 pmRNSNotice of Results
1st Apr 20057:00 amRNSTrading Statement
1st Mar 20057:01 amRNSBoard Change
18th Feb 20054:33 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.